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Abstract
Background: Because of its high sensitivity and its ease of use in the field, the card agglutination test for trypanosomiasis
(CATT) is widely used for mass screening of sleeping sickness. However, the CATT exhibits false-positive results (i) raising the
question of whether CATT-positive subjects who are negative in parasitology are truly exposed to infection and (ii) making it
difficult to evaluate whether Trypanosoma brucei (T.b.) gambiense is still circulating in areas of low endemicity. The objective
of this study was to assess the value of the immune trypanolysis test (TL) in characterising the HAT status of CATT-positive
subjects and to monitor HAT elimination in West Africa.
Methodology/Principal Findings: TL was performed on plasma collected from CATT-positive persons identified within
medical surveys in several West African HAT foci in Guinea, Co ˆte d’Ivoire and Burkina Faso with diverse epidemiological
statuses (active, latent, or historical). All HAT cases were TL+. All subjects living in a nonendemic area were TL2. CATT
prevalence was not correlated with HAT prevalence in the study areas, whereas a significant correlation was found using TL.
Conclusion and Significance: TL appears to be a marker for contact with T.b. gambiense. TL can be a tool (i) at an individual
level to identify nonparasitologically confirmed CATT-positive subjects as well as those who had contact with T.b. gambiense
and should be followed up, (ii) at a population level to identify priority areas for intervention, and (iii) in the context of HAT
elimination to identify areas free of HAT.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by two subspecies of the protozoan flagellate Trypanosoma
brucei. In West and Central Africa, T.b. gambiense causes the chronic
form of sleeping sickness, while in East Africa, T.b. rhodesiense
causes the more fulminant form [1]. T.b. brucei is normally not
infectious to humans, like other species causing animal African
trypanosomiasis (AAT) such as T. evansi, T. congolense, T. vivax and
T. equiperdum.
After the successful control campaigns dating from 1930 to
1960, T.b. gambiense sleeping sickness re-emerged in the 1980s, with
tens of thousands of cases treated every year. As a result of control
activities, reported cases decreased to a mere 11,382 patients in
2006 [2] and to less than the symbolic number of 10,000 in 2009
[3]. However, along with decreasing incidence, disease control
efforts may be discontinued, thus allowing the epidemic to build
up again [2]. At present, two West African countries are endemic
for HAT [2,4,5]. Guinea is the most affected with about 100 HAT
cases reported annually from the coastal mangroves. In Co ˆte
d’Ivoire, control activities since the 1980s [6] have resulted in a
low disease prevalence with a few tens of HAT cases annually,
mainly from the Central West foci. In Togo, Ghana, Benin, Mali
and Burkina Faso, no autochthonous cases have been reported
over the last few years. Although the epidemiological situation
remains unknown in several countries, including Liberia and
Sierra Leone, HAT elimination in West Africa seems attainable.
Mass screening of the population at risk of T.b. gambiense is
routinely performed using the card agglutination test for
trypanosomiasis (CATT) on select individuals with antibodies
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form trypomastigotes of T.b. gambiense variable antigen type (VAT)
LiTat 1.3 purified from infected rat blood, fixed, stained and
lyophilised [7]. When a drop of CATT reagent on a plastic card is
mixed for 5 min with a drop of blood or diluted plasma or serum,
the trypanosomes are agglutinated by antibodies that bind to the
surface of the fixed cells resulting in a macroscopic agglutination
reaction. Most of these antibodies will react with the VAT-specific
epitopes on the cells. These highly immunogenic epitopes are
present on the surface-exposed part of the densely packed variant
surface glycoproteins (VSG). On living trypanosomes, only these
VAT-specific epitopes are accessible for antibody binding. During
the production of CATT reagent part of the VSG coat is shed and
other epitopes on the VSG molecules that are not strictly VAT-
specific, and from other surface proteins embedded between the
VSGs, become available for antibody recognition and thus take
part in the agglutination reaction [8]. This can lead to false-
positive results, compromising the specificity of the test [9].
In the current elimination context in West Africa, when
prevalence becomes low or transmission has stopped, the limited
specificity of CATT becomes a considerable drawback because it
results in low positive predictive values [10–12]. Recognising
parasitologically unconfirmed but infected CATT-positive cases
between many false-positives becomes problematic, since untreat-
ed, they may act as a reservoir. Molecular methods such as
polymerase chain reaction (PCR), PCR-oligochromatography,
NASBA-oligochromatography, real-time PCR and loop-mediated
isothermal amplification method (LAMP) have been developed
partly to resolve the problem of these unconfirmed CATT-positive
subjects, but they also suffer from limited sensitivity, uncertain
specificity and poor reproducibility depending on the genome
sequence targeted [13–15].
In a previous study, the immune trypanolysis test (TL) was
shown to be a promising tool to help better understand the
phenomenon of nonconfirmed CATT-positive subjects [11].
Trypanosomes are able to change the VAT of their VSG by
antigenic variation [16,17]. During an infection, the host mounts
an antibody responses against a variety of VATs [18]. Some VATs
are expressed in T.b. gambiense (LiTat 1.3, LiTat 1.5 and LiTat 1.6),
others in T.b. rhodesiense (ETat 1.2). Detailed studies of trypano-
some VAT repertoires have been possible by introducing the TL,
which consists of a suspension in complement-rich cavia serum of
cloned bloodstream form trypomastigotes, all expressing the same
VAT, incubated at 37uC with a test serum. Whenever serum
antibodies bind to the VAT-specific epitopes on the trypanosome
surface, the cells are lysed through antibody-mediated comple-
ment lysis. The TL test is considered 100% specific since in the
given test conditions, only VAT-specific antibodies are able to
cause lysis of the trypanosomes and such antibodies are absent in
noninfected persons [19]. VAT repertoire studies of different
trypanosome strains have revealed that some VATs, called
predominant VATs, are recognised by almost all gambiense sleeping
sickness patients, although exceptions do occur. Thus the VAT
LiTat 1.3, corresponding to the main CATT antigen, is recognised
by all the patients in Co ˆte d’Ivoire while LiTat 1.5, representing a
different VSG type, is recognised by almost all Nigerian patients.
The combination of VATs LiTat 1.3+ LiTat 1.5+ LiTat 1.6 was
able to detect 97% of the patients from eight different countries
[19].
The objective of the present study was to evaluate the use of TL
with T.b. gambiense VATs LiTat 1.3, LiTat 1.5 and LiTat 1.6
aiming at improved epidemiological surveillance of sleeping
sickness in West Africa, with special interest in CATT-seropositive
persons. TL was performed on plasma collected during medical
surveys in several West African HAT foci. Our results argue that
TL could be used (i) as a tool to identify CATT-positive subjects
who experienced contact with T.b. gambiense and (ii) as a
surveillance tool to monitor HAT elimination.
Materials and Methods
Ethical considerations
All samples were collected within the framework of medical
surveys conducted by the national HAT control programmes
(NCP) according to the respective national HAT diagnostic
procedures. No samples other than those collected for routine
screening and diagnostic procedures were collected for the
purposes of the present study. All participants were informed of
the objective of the study in their own language and signed a
written informed consent form. Children less than 12 years old
were excluded. For participants between 12 and 18 years of age,
informed consent was obtained from their parents. This study is
part of a larger project aiming at improving HAT diagnosis for
which approval was obtained from WHO (Research Ethics
Review Committee) and Institut de Recherche pour le De ´vel-
oppement (Comite ´ Consultatif de De ´ontologie et d’Ethique)
ethical committees.
Study sites
Specimens were collected in three West African countries
(Guinea, Co ˆte d’Ivoire and Burkina Faso) in foci with a different
epidemiological HAT status (Figure 1).
Guinea. The Dubreka/Boffa focus is situated north of
Conakry in the coastal mangroves and is currently the most
active West African focus with a prevalence of about 1% [20].
The Fore ´cariah focus is situated south of Conakry in the coastal
mangroves near Sierra Leone. Sporadic HAT cases reported at
the Dubreka treatment centre come from this area.
The N’Ze ´re ´kore ´ focus is situated in the woodlands between the
savannah and the mesophilic forest near the border with Co ˆte
d’Ivoire. It is a historical HAT focus with a risk of re-emergence in
the context of socio-political instability and populations moving
between Liberia, Co ˆte d’Ivoire and Guinea. Very few recent
epidemiological data are available from this area.
Co ˆte d’Ivoire. The Bonon focus is situated in the Western
central part of the country, between the savannah and the
mesophilic forest. Between 1998 and 2003, HAT prevalence in
Author Summary
Human African trypanosomiasis (HAT) due to Trypanosoma
brucei (T.b.) gambiense is usually diagnosed using two
sequential steps: first the card agglutination test for
trypanosomiasis (CATT) used for serological screening,
followed by parasitological methods to confirm the
disease. Currently, CATT will continue to be used as a test
for mass screening because of its simplicity and high
sensitivity; however, its performance as a tool of surveil-
lance in areas where prevalence is low is poor because of
its limited specificity. Hence in the context of HAT
elimination, there is a crucial need for a better marker of
contact with T.b. gambiense in humans. We evaluated here
an existing highly specific serological tool, the trypanolysis
test (TL). We evaluated TL in active, latent and historical
HAT foci in Guinea, Co ˆte d’Ivoire and Burkina Faso. We
found that TL was a marker for exposure to T.b. gambiense.
We propose that TL should be used as a surveillance tool
to monitor HAT elimination.
Trypanolysis Test for Sleeping Sickness
www.plosntds.org 2 December 2010 | Volume 4 | Issue 12 | e917Bonon was about 0.4% [21]. From 2003 onward, HAT prevalence
of about 0.1% were observed [22].
Burkina Faso. Historical HAT foci of Folonzo, Lorope ´ni and
Batie ´ (Fol/Lor/Bat) are located in the South-western part of the
country. These areas were recently put under epidemiological
surveillance because of a risk of re-emergence of the disease due to
the return of agricultural workers from coffee plantations in Co ˆte
d’Ivoire where HAT is endemic. Tsetse flies and animal African
trypanosomiasis are still present in the area [23,24], but no HAT
cases have been reported over the last few years [25].
Study subjects
All persons participating in the study were identified during
active screening campaigns organised by the NCPs in Guinea,
Burkina Faso and Co ˆte d’Ivoire during HAT surveillance
activities. Only subjects positive to the CATT/T.b. gambiense
(CATT-B) performed on blood collected by finger prick and who
had never received HAT-specific treatment were included in the
study. For CATT-B-positive persons, blood was collected in
heparinised tubes and a twofold plasma dilution series in CATT
buffer was tested to assess the end titre, i.e. the highest dilution still
positive (CATT-P). All persons included in the study underwent
parasitological examinations by direct examination of the lymph
node aspirate and/or mini-anion exchange centrifugation tech-
nique (mAECT) on blood [26]. Thus, three categories of study
participants were defined for the purposes of the study:
HAT (patients): CATT-P end titer $1/8 and parasitologically
confirmed;
SERO (seropositives): CATT-P end titer $1/8 but no parasites
detected;
SUSP (suspects): CATT-B-positive and CATT-P ,1/8 but no
parasites detected.
The origin and numbers of participants in each group are
detailed in Table 1. Left-over plasma specimens from the subjects
were kept at 220uC during field activities, stored at 280uC in the
Centre de Recherche De ´veloppement sur l9Elevage en zone
Subhumide (CIRDES, Bobo-Dioulasso, Burkina-Faso) and sent on
dry ice to the Institute of Tropical Medicine (ITM, Antwerpen,
Belgium) where TL was performed blindly.
Trypanolysis test
Cloned populations of T.b. gambiense VATs LiTat1.3, LiTat 1.5
and LiTat 1.6 and one T.b. rhodesiense VAT ETat 1.2R were used
to test plasma as previously described [19]. Briefly, 25 ml of plasma
was mixed with an equal volume of guinea pig serum, to which
50 mlo fa1 0
7 trypanosomes/ml suspension prepared from
infected mouse blood was added. After 90 min of incubation at
room temperature, the suspension was examined by microscopy
(6250). Trypanolysis was considered positive when more than
50% of the trypanosomes were lysed. ETat 1.2R was a control for
the absence of nonspecific trypanolytic activity of the test plasma.
Plasma were considered positive (TL+) if positive with at least one
of the three variants.
Figure 1. Localisation of sampling areas.
doi:10.1371/journal.pntd.0000917.g001
Table 1. Study subjects according to the HAT focus and HAT
status.
Country Focus SUSP SERO HAT Total
Guinea Dubreka/Boffa 0 17 37 54
Guinea Fore ´cariah 0 30 28 58
Co ˆte d’Ivoire Bonon 86 24 6 116
Guinea N’Ze ´re ´kore ´ 01 60 1 6
Burkina Faso Fol/Lor/Bat 18 25 0 43
Total 104 112 71 287
Fol/Lor/Bat = Folonzo, Lorope ´ni and Batie ´.
SUSP, SERO and HAT are defined in the Materials and Methods section.
doi:10.1371/journal.pntd.0000917.t001
Trypanolysis Test for Sleeping Sickness
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CATT-B and CATT-P
A total of 43,373 persons were screened with CATT/T.b.
gambiense (Table 2). The highest HAT prevalence was observed in
Dubreka-Boffa. Low prevalence was observed in Fore ´cariah and
Bonon. No patients were detected at the three study sites in
Burkina Faso (Fol/Lor/Bat) and N’Ze ´re ´kore ´ in Guinea. Sero-
prevalence of CATT-B and CATT-P end titer 1/8 or higher-
ranged from 0.95 to 3.87% and from 0.31 to 1.21%, respectively,
and were not associated with disease prevalence (CATT-B:
r
2=0.05, p=0.91; CATT-P end titer $1/8: r
2=0.26, p=0.37).
Trypanolysis test
The results of TL on the 287 subjects included in the study are
summarised in Table 3. No serum lysed T.b. rhodesiense VAT ETat
1.2R, indicating the absence of non-antibody-related trypanolytic
factors in the plasma samples.
All 71 HAT patients were TL+. All 18 SUSP from For/Lor/Bat
in Burkina Faso were TL2 while in Bonon 10 of 86 (11.6%) were
TL+. Among the SERO subjects, 41 of 112 (36.6%) were TL+.
Interestingly, the percentage of TL+ subjects in the SERO group
was correlated with HAT prevalence (r
2=0.84, p=0.03) (Figure 2).
It was the highest in the epidemic context of Dubreka/Boffa (15/
17, 88.2%), lower in areas of lower HAT prevalence (18/30, 60%
and 7/24, 29.2% in Fore ´cariah and Bonon, respectively), whereas
no TL+ subjects were detected in areas were HAT was absent,
except for one subject in the Fol/Lor/Bat area in Burkina Faso.
Table 4 presents the TL results per VAT for TL+ persons by study
site. In Bonon, all HAT and SERO subjects were positive for all
VATs. Among the ten SUSP, six were also positive for all VATs,
whereas four showed different profiles. In Guinea, all 58 of 58
HAT were positive for LiTat 1.3 and LiTat 1.5 and only 38 of 58
were positive in LiTat 1.6. The same trends were observed for
SERO: 32 of 33 were positive for LiTat 1.3 and LiTat 1.5 and
only 12 of 33 were positive in LiTat 1.6.
Discussion
This study shows that high prevalence of CATT-positive
individuals can be found even in areas were transmission has
stopped, presumably owing to false positivity. On the contrary,
positivity of TL in SERO subjects was significantly correlated with
HAT prevalence and not in nonendemic areas. Thus TL is a
useful tool, both to define the epidemiological status of an area
when no HAT cases are diagnosed and to improve the monitoring
of CATT-positive subjects with no parasitological confirmation,
who are currently left out of HAT control strategies in most
endemic countries.
CATT and epidemiological surveillance
The HAT prevalence rates observed in this study are in
agreement with recent data on HAT epidemiology in West Africa.
Guinea was the most affected country, with 0.57% HAT
prevalence in Dubreka-Boffa and 0.16% in the Fore ´cariah focus.
No HAT cases were diagnosed in the N’Ze ´re ´kore ´ focus. With
0.18% prevalence, HAT is still endemic in the Bonon focus in
Co ˆte d’Ivoire. The disease did not re-emerge in the historical foci
Table 2. Results of the medical surveys: sero-prevalence and HAT prevalence.
Study site Examined population CATT-B pos CATT-P pos HAT
number % number % number %
Dubreka/Boffa 6795 124 1.82 56 0.82 39 0.57
Fore ´cariah 17571 167 0.95 63 0.36 28 0.16
Bonon 3305 128 3.87 40 1.21 6 0.18
N’Ze ´re ´kore ´ 4853 102 2.10 16 0.33 0 0.00
Fol/Lor/Bat 10849 132 1.22 34 0.31 0 0.00
Total 43373 653 1.51 209 0.48 73 0.17
Fol/Lor/Bat = Folonzo, Lorope ´ni and Batie ´; pos = positive.
CATT-P pos = CATT-P end titer $1/8.
doi:10.1371/journal.pntd.0000917.t002
Table 3. TL results according to the study area and status.
Category SUSP SERO HAT
Study sites Prev TL+ TL- %TL+ TL+ TL- %TL+ TL+ TL- %TL+
Dub/Bof 0.57% 0 0 na 15 2 88.2 37 0 100
Fore ´cariah 0.16% 0 0 na 18 12 60 28 0 100
Bonon 0.18% 10 76 11.6 7 17 29.2 6 0 100
N’Ze ´re ´kore ´ 0.00% 0 0 na 0 16 0 0 0 na
Fol/Lor/Bat 0.00% 0 18 0 1 24 4 0 0 na
Total 10 94 9.6 41 71 36.6 71 0 100
Dub/Bof = Dubreka/Boffa; Fol/Lor/Bat = Folonzo, Lorope ´ni and Batie ´, prev = HAT prevalence; na = not available; SUSP, SERO and HAT are defined in the Materials and
Methods section.
doi:10.1371/journal.pntd.0000917.t003
Trypanolysis Test for Sleeping Sickness
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active HAT foci in Co ˆte d’Ivoire since 2002 [25]. In West Africa,
areas with disease prevalence approaching zero are becoming
common, a recent trend observed in savannah areas [4]. In such
areas, CATT-seropositive but parasitologically unconfirmed
persons are encountered, making it difficult to evaluate the
epidemiological status of the area and to determine what control
measures should be applied at both the population and individual
levels. This is clearly illustrated by the fact that SERO persons
were found in all study sites but their number was not correlated
with HAT prevalence (Figure 2). In the historical foci of Burkina
Faso and in N’Ze ´re ´kore ´ where transmission has stopped, SERO
persons may be regarded as false-positives. Aspecific reactions in
CATT may have different causes [14] such as cross-reactions with
other infectious diseases or transient infections with T. b. brucei.
Interestingly, the proportion of SERO subjects is highest in Bonon
where pig breeding is widespread and where the prevalence of T.b.
brucei in domestic pigs was reported to be around 70% [27]. Wild
fauna and T.b. brucei are still present in South-west Burkina Faso
[24], where the prevalence of SERO observed in this study is also
relatively high. On the other hand, few domestic animals are kept
in the Dubreka/Boffa and Fore ´cariah foci in Guinea, where the
proportion of SERO is the lowest but which display the highest
HAT prevalence. Thus, although CATT is a good serological test
for active screening, CATT seropositivity prevalence is not
correlated with HAT prevalence, and CATT is not specific
enough to evaluate whether T.b. gambiense is still circulating in a
given area, which is of paramount importance in a disease
elimination context.
Contribution of TL to HAT surveillance
TL was found to be highly sensitive (100% of HAT cases were
TL+). Among SUSP and SERO persons, TL+ individuals were
only found in areas with proven transmission, except one SERO
person in the Fol/Lor/Bat focus in Burkina Faso, which is no
longer active. It is noteworthy that this person had worked for 4
years in coffee and cacao plantations in a known HAT focus in
Co ˆte d’Ivoire where he may have been exposed to T.b. gambiense.
Furthermore, a significant correlation was found between the
percentage of TL+ SERO persons and the observed HAT
Figure 2. Trypanolysis test is a marker of active HAT transmission. South Western Burkina = Folonzo, Lorope ´ni and Batie ´. The left Y-axis
represents the prevalence of HAT (number of HAT cases/examined population) and SERO (number of subjects with CATT-P end titer $1/8 but no
parasites detected/examined population). The right Y-axis represents the proportion of SERO individuals that were positive to the trypanolysis test.
doi:10.1371/journal.pntd.0000917.g002
Table 4. VAT-specific TL-positive profiles according to study
site and HAT status.
LiTat SUSP SERO HAT
Study sites 1.3 1.5 1.6 nb nb nb
Dubreka/Boffa ++ +na 10 30
++ 2 na 5 7
Fore ´cariah ++ +na 2 15
++ 2 na 15 13
+ 22 na 1 0
Bonon ++ +67 6
++ 2 10 0
+ 2 + 10 0
+ 22 10 0
22 + 10 0
Fol/Lor/Bat ++ +01 n a
Fol/Lor/Bat = Folonzo, Lorope ´ni and Batie ´; nb = number; na = not available;
SUSP, SERO and HAT are defined in the Materials and Methods section.
doi:10.1371/journal.pntd.0000917.t004
Trypanolysis Test for Sleeping Sickness
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of exposure to T.b. gambiense than CATT. The higher specificity of
TL observed in this study is explained by the fact that only VAT-
specific epitopes can react with antibodies in this test format.
Other studies indicated that TL can be more sensitive than CATT
since parallel testing with several VATs (LiTat 1.3, 1.5 and 1.6)
may reveal infections by T.b. gambiense strains not expressing LiTat
1.3, the VAT used for CATT preparation [19,28]. In addition, TL
is based on antibody-mediated complement lysis and can therefore
detect much lower antibody concentrations than CATT, which is
based on agglutination reactions (unpublished data).
Assuming TL is a marker of exposure to T.b. gambiense, the
existence in HAT endemic areas of persons harboring T.b.
gambiense-specific antibodies detectable by TL but without
detectable parasites may be explained by one of several
hypotheses:
(1) These individuals could be patients in an early step of
infection with as yet undetectable trypanosomes in blood,
lymph or cerebrospinal fluid.
(2) They could be asymptomatic carriers with very low
parasitaemia. In this study, 53% of the SERO TL+ persons
were positive on PCR using the TBR1/2 primers [29] and
may actually be infected (data not shown). Asymptomatic
infections with undetectable parasitaemia may occur in
persons with particular genetic characteristics [12] or be
caused by particular T.b. gambiense strains inducing silent
infections, as demonstrated in mice infected with strains from
Co ˆte d’Ivoire [30].
(3) They could have experienced a transient episode of T.b.
gambiense infection, cleared by self-cure or by unreported
nonspecific (e.g. autochthonous) treatment. Indeed, in HAT,
antibodies may remain present for years after successful cure
[10].
Concordant with TL positivity being a marker of contact with
T.b. gambiense is the fact that lysis profiles to the different LiTat
VATs tested were similar in HAT patients and SERO individuals
in the different endemic areas. In Co ˆte d’Ivoire, all SERO and
HAT patients were positive for all three LiTat VATs. This was not
the case in Guinea where only a fraction of HAT patients were
positive for LiTat 1.6, as observed in SERO individuals.
Implication for HAT control strategies
At the individual level, TL can represent a tool for NCPs to
identify among CATT-positives those who should be followed up
by CATT and parasitological investigations until CATT becomes
negative or the person is confirmed as a HAT patient. Whether
these seropositives should undergo treatment remains an open
question as long as their role in HAT transmission is unknown. We
are currently carrying out follow-ups of SERO subjects.
Preliminary results indicate that SERO TL+ individuals maintain
a strong serological response (CATT and TL) over time, whereas
SERO TL2 subjects become CATT-negative within several
months. Furthermore, HAT patients confirmed during these
follow-ups were all from the SERO TL+ cohort (Bucheton,
personal communication). In some countries, treatment of
unconfirmed persons with CATT-P titers $1/16 is already
recommended [10]. TL on these persons may avoid unnecessary
treatments, as suggested by the nine, five and eight persons in Co ˆte
d’Ivoire, Guinea and Burkina Faso, respectively, who had CATT-
P titers $1/16 but were TL2 (data not shown).
At the population level, TL performed on CATT-positive
individuals could be a valuable decision tool for NCPs to plan
control measures (Figure 3). In active HAT foci, the priority is
cutting transmission through active screening and vector control,
thus SERO TL+ individuals should be monitored and treated
when they become parasitologically positive. Also in areas without
HAT, the presence of SERO TL+ cases should sound an alarm,
Figure 3. Control strategies: use of trypanolysis test as a marker of T.b. gambiense transmission. HAT = presence of HAT cases; No HAT
= absence; SERO = presence of subjects with CATT-P end titer $1/8 but no parasites detected, No SERO = absence; TL+ = positive in trypanolysis
test; TL2 = negative; * except for a special event, such as population movements, occurs.
doi:10.1371/journal.pntd.0000917.g003
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surveillance of such areas is therefore strongly indicated. In areas
without HAT and without SERO TL+ cases, HAT transmission
may be considered absent and surveillance may be suspended
unless a special event, such as population movement, occurs.
From a practical point of view, the implementation of TL in
NCP is hampered by its technological requirements (cryobiology
and laboratory animal facilities, availability of VAT-specific
control sera, etc.). An alternative test that is applicable in the
field and that allows combining several VATs in a single test is the
indirect agglutination test LATEX/T.b. gambiense [31]. Unfortu-
nately, the purified native VSGs used as antigens in the LATEX/
T.b. gambiense bear non-VAT-specific epitopes that can lead to
false-positive reactions as in the CATT. Investigations to eliminate
these non-VAT-specific epitopes in rapid diagnostic tests for HAT
are ongoing. In the meantime, adaptation of TL for testing blood
collected on filter paper is underway. This would facilitate
specimen storage and shipment from the field to the laboratory,
as was done for T. evansi [32]. Furthermore, as in West Africa
almost all TL+ persons are positive in LiTat 1.3, TL with this
VAT alone may be sufficient for surveillance purposes in this
region. During a WHO meeting held in Bamako in June 2009
with representatives of disease-endemic countries and partners
involved in HAT control in West Africa, sleeping sickness control
managers welcomed the performance of TL and stated their
willingness to collect plasma specimens from SERO cases detected
during medical surveys, and send them to CIRDES where TL is
now available.
In conclusion, application of the TL test within the framework
of medical surveys has provided a better picture of HAT
epidemiology in West Africa, thanks to a better characterisation
of parasitologically unconfirmed CATT positive subjects. The
proportion of TL+ subjects among CATT+ individuals was
associated with active HAT foci and can thus be used as a marker
for exposure to T.b. gambiense even in areas were no HAT cases are
currently being diagnosed. TL could thus be regarded as a
decision tool for NCPs to decide when surveillance or disease
control should be stopped in a given area. The results presented
here encourage further investigations, including other endemic
countries; into the significance of TL as a tool for improve the
knowledge of HAT epidemiology and control.
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